JP2022554353A5 - - Google Patents

Info

Publication number
JP2022554353A5
JP2022554353A5 JP2022525990A JP2022525990A JP2022554353A5 JP 2022554353 A5 JP2022554353 A5 JP 2022554353A5 JP 2022525990 A JP2022525990 A JP 2022525990A JP 2022525990 A JP2022525990 A JP 2022525990A JP 2022554353 A5 JP2022554353 A5 JP 2022554353A5
Authority
JP
Japan
Prior art keywords
pharmaceutical product
administration
product according
cells
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022525990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554353A (ja
JP7837864B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059550 external-priority patent/WO2021092498A1/en
Publication of JP2022554353A publication Critical patent/JP2022554353A/ja
Publication of JP2022554353A5 publication Critical patent/JP2022554353A5/ja
Priority to JP2026044585A priority Critical patent/JP2026102809A/ja
Application granted granted Critical
Publication of JP7837864B2 publication Critical patent/JP7837864B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525990A 2019-11-07 2020-11-06 Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用 Active JP7837864B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026044585A JP2026102809A (ja) 2019-11-07 2026-03-18 Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962932500P 2019-11-07 2019-11-07
US62/932,500 2019-11-07
US202063016977P 2020-04-28 2020-04-28
US63/016,977 2020-04-28
PCT/US2020/059550 WO2021092498A1 (en) 2019-11-07 2020-11-06 Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026044585A Division JP2026102809A (ja) 2019-11-07 2026-03-18 Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用

Publications (3)

Publication Number Publication Date
JP2022554353A JP2022554353A (ja) 2022-12-28
JP2022554353A5 true JP2022554353A5 (cg-RX-API-DMAC10.html) 2023-11-15
JP7837864B2 JP7837864B2 (ja) 2026-03-31

Family

ID=73699424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525990A Active JP7837864B2 (ja) 2019-11-07 2020-11-06 Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用
JP2026044585A Pending JP2026102809A (ja) 2019-11-07 2026-03-18 Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026044585A Pending JP2026102809A (ja) 2019-11-07 2026-03-18 Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用

Country Status (10)

Country Link
US (1) US20220401483A1 (cg-RX-API-DMAC10.html)
EP (1) EP4054623A1 (cg-RX-API-DMAC10.html)
JP (2) JP7837864B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220122615A (cg-RX-API-DMAC10.html)
CN (1) CN114980918A (cg-RX-API-DMAC10.html)
AU (1) AU2020379043A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022007548A2 (cg-RX-API-DMAC10.html)
IL (1) IL292667B2 (cg-RX-API-DMAC10.html)
MX (1) MX2022005524A (cg-RX-API-DMAC10.html)
WO (1) WO2021092498A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
CA3181399A1 (en) * 2020-04-28 2021-11-04 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ATE114507T1 (de) 1988-12-28 1994-12-15 Stefan Miltenyi Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
DE4228458A1 (de) 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
US7446179B2 (en) 2000-11-07 2008-11-04 City Of Hope CD19-specific chimeric T cell receptor
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US8389282B2 (en) 2007-03-30 2013-03-05 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
EP2520643B8 (en) 2007-12-07 2019-11-27 Miltenyi Biotec B.V. & Co. KG Sample processing systems and methods
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
SG183257A1 (en) 2010-02-11 2012-09-27 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013071154A1 (en) 2011-11-11 2013-05-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
UA116544C2 (uk) 2012-08-09 2018-04-10 Селджин Корпорейшн Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
LT2882737T (lt) * 2012-08-09 2019-04-25 Celgene Corporation (s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
LT2884999T (lt) 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
RU2729401C2 (ru) 2012-10-02 2020-08-06 Мемориал Слоан-Кеттеринг Кэнсер Сентер Композиции и способы для иммунотерапии
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
UA117141C2 (uk) 2013-10-08 2018-06-25 Селджин Корпорейшн Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
MA45784A (fr) 2016-07-29 2019-06-05 Juno Therapeutics Inc Anticorps anti-idiotypes dirigés contre anti-cd19 anticorps
PL3618842T3 (pl) 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合

Similar Documents

Publication Publication Date Title
AU2017302668B2 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
AU2013289967B2 (en) Toxicity management for anti-tumor activity of CARs
JP2023519099A5 (cg-RX-API-DMAC10.html)
JP2021512107A5 (cg-RX-API-DMAC10.html)
EP3407911B1 (en) Methods and pharmaceutical composition for the treatment of cancer
JP2022512917A5 (cg-RX-API-DMAC10.html)
FI3886875T3 (fi) Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
JP2021523122A5 (cg-RX-API-DMAC10.html)
JP7704748B2 (ja) 逐次抗ｃｄ１９治療
JP2023522857A5 (cg-RX-API-DMAC10.html)
JP2025134707A5 (cg-RX-API-DMAC10.html)
JP2023524430A5 (cg-RX-API-DMAC10.html)
JP2024540275A5 (cg-RX-API-DMAC10.html)
JP2022513062A5 (cg-RX-API-DMAC10.html)
JP2024513054A5 (cg-RX-API-DMAC10.html)
JP2023513434A5 (cg-RX-API-DMAC10.html)
JP2023524068A5 (cg-RX-API-DMAC10.html)
JP2024514163A5 (cg-RX-API-DMAC10.html)
JP2024540320A5 (cg-RX-API-DMAC10.html)
CA3127142A1 (en) Cancer immunotherapy using combinations of cells expressing chimeric antigen receptors and monoclonal antibodies
WO2025120866A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2026033885A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
EA048837B1 (ru) Ступенчатая анти-cd19 терапия
WO2025121445A1 (en) Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
HK40116181A (en) Toxicity management for anti-tumor activity of cars